MedTrace Logo

[18F]FPIA PET-CT in Glioblastoma Multiforme (GBM)

NCT05801159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2025-04-09

No results posted yet for this study

Summary

Glioma is the most common primary malignant brain tumour in adults and has an extremely poor prognosis. Glioblastoma is the most common subtype and its most aggressive form, with an annual incidence of 3.19 cases per 100,000.

The aim of this study is to quantify the degree of fatty acid oxidation in 20 participants diagnosed with glioblastoma multiforme (GBM) that have undergone surgical resection throughout the course of their chemotherapy and radiotherapy treatment.

The investigators hypothesise that the parameters derived from longitudinal 18F-fluoropivalate (18F-FPIA) positron emission tomography (PET) will change predictably over the course of therapy in relation to response.

Conditions

  • Glioblastoma Multiforme of Brain

Interventions

DIAGNOSTIC_TEST

Positron Emission Tomography-Computerised Tomography (PET-CT)

Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Matthew Williams · Imperial College Healthcare NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2025-04-02
Completion
2025-04-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05801159 on ClinicalTrials.gov